-up report of the impact of therapy in 576 patients.// Am J Med; 1981 70 (3) :511-18. p> McDougall I.R. 131I treatment of 131I negative whole-body scan, and positive thyroglobulin in differentiated thyriod carcinoma: what is being treated? // Thyriod; 1997 7 (4) :669-72
McDougall I.R. Whole-body scintigraphy with radioiodine-131. A comprehensive list of false-positives with some examples. // Clin Nucl Med; 1995 20 (10) :869-75
Melliere D., Berrahal D., Hindie E., et al. Surveillance after treatment of differentiated thyroid cancers. // Ann Chir; 2000 125 (9) :856-60
Menzel C., Grunwald F., Schomburg A., et al. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma. // J Nucl Med; 1996 37 (9) :1496-503
Miyamoto S., Kasagi K., Endo K., et al. Resalts of radioiodine therapy in 47 patients with distant metastases of differentiated thyriod carcinoma. // Nippon Igaku Hoshasen Gakkai Zasshi; 1991 51 (7) :810-21
M'Kacher R., Schlumberger M., Lregal JD, et al. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.// J Nucl Med; 1998 39 (5) :825-9
Morris L.F., Waxman A.D., Braunstein G.D. The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. // J Clin Endocrinol Metab; 2001 86 (8) :3507-11
Muratet J.P. Giraud P., Daver А., et al. Predicting the efficacy of first iodine-131 treatment in differentiated thyriod carcinoma. // J Nucl Med; 1997 38 (9) :1362-8
Muratet J.P., Daver А., Minier J.F., Larra F. Influence of scanning dose of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyriod carcinoma. // J Nucl Med 1998; 39 (9) :1546-50
North DL, Shearer DR, Hennessey JV, Donovan GL Effective half-life of 131I in thyroid cancer patients. // Health Phys; 2001 81 (3) :325-9
O `Connel ME, Flover M, A,, Hinton P, J., et al. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyriod carcinoma using quantitive scanning and PET. // Radiother Oncol; 1993 28 (1) :16-26
O `Doherty M.J., Coakley A.J. Drug therapy alternatives in the treatment of thyriod cancer. // Drugs; 1998 55 (6) :801-12
Ozaki O., Ito K., Manabe Y., et al. Clinical study on pulmonary metastases of differentiated thyriod carcinoma - with special reference to the extent of thyriod resection and RI therapy. // Nippon Geka Gakkai Zasshi; 1985 86 (12) :1596-9
Paloyan E., Walker R.P., Lawrence A.M. Guidelines for the use of radioiodine, thyriod hormone, and treatment of metastatic disease in patients with differentiated thyriod cancer. // Surg Oncol Clin N Am; 1998 7 (4) :665-80
Paryani S.B., Chobe R.J., Scott W., et al. Manegement of thyroid carcinoma with radioactive 131I. // J Radiat Oncol Biol Phys; 1996 36 (1) :83-6
Pelican DM, Lion HL, Hermans J., Gosling...
